BMS Submits Application for Abecma® for Relapsed or Refractory Multiple Myeloma
LifeProNow
APRIL 19, 2023
Monitor for neurologic events after treatment with ABECMA. Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with ABECMA. and Europe.” Provide supportive care and/or corticosteroids as needed.
Let's personalize your content